Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of...

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed diffuse large B-cell lymphoma (DLBCL) poses treatment challenges.
• Epcoritamab is a bispecific CD3xCD20 antibody with potential in DLBCL.
• Efficacy and safety of epcoritamab after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are not well-established.

Purpose of the Study:

• To evaluate the efficacy and safety of epcoritamab in a patient with relapsed DLBCL.
• To explore the potential of epcoritamab as a salvage therapy post-allo-HSCT.

Main Methods:

• Case report of a 64-year-old male patient with relapsed DLBCL.
• Administration of epcoritamab prior to and after allo-HSCT.
• Monitoring for treatment response, graft-versus-host disease (GVHD), and cytokine release syndrome (CRS).

Main Results:

• Epcoritamab showed limited efficacy (stable disease) before allo-HSCT.
• Following allo-HSCT and donor T-cell engraftment, re-administration of epcoritamab resulted in a complete response.
• No severe GVHD or CRS was observed during post-transplant epcoritamab treatment.

Conclusions:

• Epcoritamab, when used post-transplant after donor T-cell engraftment, may enhance antitumor activity.
• This approach suggests a potential role for epcoritamab as a salvage therapy for relapsed DLBCL post-allo-HSCT.
• Donor T-cell redirection with epcoritamab appears safe and effective in this setting.